Handbook of HER2-Targeted Agents in Breast Cancer

Ricardo Alvarez is Director of Clinical Research and Breast Cancer Specialist at Cancer Treatment Centers of America in Atlanta, Georgia. Javier Cortes is Deputy Director of the Breast Cancer Program, Head of the Breast Cancer and Melanoma Group in the Oncology Department of Vall d'Hebron University Hospital in Barcelona, Spain. Mary Falzon is Consultant histo/cytopathologist and Divisional Clinical Director for University College London Hospitals in London, UK. Michael Gandy is lead biomedical scientist and clinical services manager at University College London- Advanced Diagnostics in London, UK. Luca Gianni is the Director of the Department of Medical Oncology at the Hospital San Raffaele in Milan, Italy. Nadia Harbeck is Head of the Breast Center at the University of Munich and heads the Oncological Therapy and Clinical Trials Unit in Obstetrics and Gynecology in Munich, Germany. Martine Piccart is Professor of Oncology at the Université Libre de Bruxelles and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium.

Introduction and background biology.- HER2 testing.- HER2-positive breast cancer: neoadjuvant and adjuvant therapy.- HER2-positive metastatic breast cancer: first-line treatment.- HER2-positive metastatic breast cancer: second-line treatment.- Emerging targeted agents for HER2-positive breast cancer.